Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors

Madero-Marroquin, Rafael; DuVall, Adam S.; Saygin, Caner; Wang, Peng; Gurbuxani, Sandeep; Larson, Richard A.; Stock, Wendy; Patel, Anand Ashwin

doi:10.6082/bwkb5-dk250

Published December 10, 2023 | Version v1

Journal article Open

Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors

1. University of Chicago

Data regarding the use of FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in acute lymphoblastic leukaemia (ALL) are lacking. We identified 14 patients with FLT3- or IDH1/2-mutated ALL. Three early T-cell precursor-ALL patients received FLT3 or IDH2 inhibitors. Patient 1 maintains a complete remission (CR) with enasidenib after intolerance to chemotherapy. Patient 2 maintained a CR for 27 months after treatment with enasidenib for relapsed disease. Patient 3 was treated with venetoclax and gilteritinib at the time of relapse and maintained a CR with gilteritinib for 8 months. These cases suggest that FLT3 and IDH inhibitors could represent a viable therapeutic option for ALL patients with these mutations.

Data availability

For original data, please contact Anand Ashwin Patel.

Files